Sublingual Immunotherapy in Patients With Atopic Dermatitis

Usefulness and Safety of Sublingual Dermatophagoides Farinae Drops in Patients With Atopic Dermatitis:A Randomized,Double-blind,Placebo-controlled Study.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01471119

Enrollment

239

Registered

2011-11-11

Start date

2011-10-31

Completion date

2015-06-30

Last updated

2018-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Keywords

sublingual immunotherapy, atopic dermatitis, Dermatophagoides Farinae Drops

Brief summary

To assess the effect and safety of sublingual Dermatophagoides Farinae Drops in adult patients with atopic dermatitis and allergic sensitization to house dust mites.240 adults age 18 to 60 years with atopic dermatitis(Objective Scoring Atopic Dermatitis, Objective SCORAD from 10 to 40) are going to be enrolled in a randomized,double-blind,placebo-controlled study.Sublingual Dermatophagoides Farinae Drops or placebo is given for 9 months in addition to standard therapy.SCORAD,average anesis interval,rescue medicine and DLQI will be recorded.

Detailed description

SCORAD is composed of skin rash area,severity and subjective symptom including pruritus and sleeping quality.Skin rash area and severity score are objective SCORAD(range from 0 to 83).Subjective SCORAD range from 0 to 20 and total SCORAD range from 0 to 103.

Interventions

BIOLOGICALDermatophagoides Farinae Drops Group 1

Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.

BIOLOGICALDermatophagoides Farinae Drops Group 2

Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drop of placebo.

BIOLOGICALDermatophagoides Farinae Drops Group 3

Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.

BIOLOGICALPlacebo

Placebo Group is the group with maintenance dose of 3 drops of placebo.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Patients of either sex ,aged from 18 to 60 years. Diagnosed of atopic dermatitis. * Mild to moderate AD ( \[SCORAD\] 1O-40) * The results of skin prick tests with dermatophagoides farinae allergen extracts preparation is positive(≥2+) * Written informed consent by the subject or legal guardian. * Female patients of child-bearing potential must be negative pregnant test on screening and use an appropriate method of contraception.

Exclusion criteria

* Dust mites are not the primary allergens. * Pregnant, breastfeeding women or women planned to pregnant within 1 year. * Have concurrent skin disease that it could interfere with the study evaluation. * Were treated with antihistamines or topical therapy within 7 days of randomization. * Have received systemic corticosteroids,leukotriene receptor antagonists or immunosuppressants within 4 weeks of randomization. * Have received phototherapy (e.g. UVA, UVB) within 4 weeks of randomization. * Have a history of immune suppressed diseases(malignant tumor or infection of HIV), autoimmune disease or tuberculosis. * Patients with impaired liver function (aspartate aminotransferase and/ or alanine aminotransferase levels 1.5 times the upper limit of normal), impaired renal function(serum creatinine\>normal value) or other severe diseases. * Bronchial asthma patients who need treatments with corticosteroids and or β agonists(including injection, oral administration or inhalation) regularly. * Patients who need to take β-blockers during research. * Have received investigational drugs within 3 months prior to randomization or planned use of other investigational drugs during participation in this study. * Have received immunotherapy with dust mite preparation within 3 years prior to randomization. * Patients with severe mental disorders.

Design outcomes

Primary

Measure	Time frame	Description
average anesis interval	baseline and 36 week	The average duration of last 3 whole anesis interval.
Rescue medication consumption	36 week	The total sum of rescue medication consumption will be recorded.
SCORAD	baseline and 36 week	Change of SCORAD will be assessed.

Secondary

Measure	Time frame	Description
DLQI	baseline and 36 week	Change of Dermatology Life Quality Index will be assessed.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026